التفاصيل البيبلوغرافية
| العنوان: |
Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia. |
| المؤلفون: |
Anderson, Stacey M.1 sg4c@virginia.edu, Buckingham, Bruce A.2, Breton, Marc D.1, Robic, Jessica L.1, Barnett, Charlotte L.1, Wakeman, Christian A.1, Oliveri, Mary C.1, Brown, Sue A.1, Ly, Trang T.2, Clinton, Paula K.2, Hsu, Liana J.2, Kingman, Ryan S.2, Norlander, Lisa M.2, Loebner, Sarah E.2, Reuschel-DiVirglio, Suzette2, Kovatchev, Boris P.1 |
| المصدر: |
Diabetes Technology & Therapeutics. Jun2019, Vol. 21 Issue 6, p356-363. 8p. |
| مصطلحات موضوعية: |
*TYPE 1 diabetes, *INSULIN pumps, *HYPOGLYCEMIA, *BLOOD sugar |
| الشركة/الكيان: |
UNIVERSITY of Virginia |
| مستخلص: |
Background: Typically, closed-loop control (CLC) studies excluded patients with significant hypoglycemia. We evaluated the effectiveness of hybrid CLC (HCLC) versus sensor-augmented pump (SAP) in reducing hypoglycemia in this high-risk population. Methods: Forty-four subjects with type 1 diabetes, 25 women, 37 ± 2 years old, HbA1c 7.4% ± 0.2% (57 ± 1.5 mmol/mol), diabetes duration 19 ± 2 years, on insulin pump, were enrolled at the University of Virginia (N = 33) and Stanford University (N = 11). Eligibility: increased risk of hypoglycemia confirmed by 1 week of blinded continuous glucose monitor (CGM); randomized to 4 weeks of home use of either HCLC or SAP. Primary/secondary outcomes: risk for hypoglycemia measured by the low blood glucose index (LBGI)/CGM-based time in ranges. Results: Values reported: mean ± standard deviation. From baseline to the final week of study: LBGI decreased more on HCLC (2.51 ± 1.17 to 1.28 ± 0.5) than on SAP (2.1 ± 1.05 to 1.79 ± 0.98), P < 0.001; percent time below 70 mg/dL (3.9 mmol/L) decreased on HCLC (7.2% ± 5.3% to 2.0% ± 1.4%) but not on SAP (5.8% ± 4.7% to 4.8% ± 4.5%), P = 0.001; percent time within the target range 70-180 mg/dL (3.9-10 mmol/L) increased on HCLC (67.8% ± 13.5% to 78.2% ± 10%) but decreased on SAP (65.6% ± 12.9% to 59.6% ± 16.5%), P < 0.001; percent time above 180 mg/dL (10 mmol/L) decreased on HCLC (25.1% ± 15.3% to 19.8% ± 10.1%) but increased on SAP (28.6% ± 14.6% to 35.6% ± 17.6%), P = 0.009. Mean glucose did not change significantly on HCLC (144.9 ± 27.9 to 143.8 ± 14.4 mg/dL [8.1 ± 1.6 to 8.0 ± 0.8 mmol/L]) or SAP (152.5 ± 24.3 to 162.4 ± 28.2 [8.5 ± 1.4 to 9.0 ± 1.6]), P = ns. Conclusions: Compared with SAP therapy, HCLC reduced the risk and frequency of hypoglycemia, while improving time in target range and reducing hyperglycemia in people at moderate to high risk of hypoglycemia. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
